Group B streptococcus
Group B streptococcus
复制标题
DOI：
10.1016/s0140-6736(98)07128-1
复制
发表时间：
1999-01-02
期刊：
影响因子：
168.9
通讯作者：
Schuchat, A
中科院分区：
文献类型：
--
作者：
Schuchat, A
在20世纪90年代，B组链球菌（GBS）疾病研究的重点已经转移到预防。在北美和澳大利亚，分娩时预防性抗菌药物的使用增加，导致围产期疾病大幅下降。疫苗开发（20年前开始）已经取得了成果，例如，给育龄妇女接种的多糖蛋白结合疫苗被证明具有高度免疫原性和良好的耐受性。此外，经济评价还评估了预防战略在不同人群中的成本效益。虽然GBS传统上被认为是围产期病原体，侵袭性GBS疾病的负担在非妊娠成人已被测量。通过一项多中心研究，证实了GBS大量定植在早产低出生体重分娩中的重要作用。最后，病原体本身也在继续进化：过去十年中描述的新的荚膜血清型现在正在引起重要比例的临床感染。
During the 1990s the focus of group B streptococcus (GBS) disease research has shifted to prevention. increased use of intrapartum antimicrobial prophylaxis in North America and Australia has led to substantial declines in perinatal disease. Vaccine development (initiated two decades earlier) has yielded results-for example, polysaccharide-protein conjugate vaccines given to women of reproductive age proved to be highly immunogenic and well tolerated. Also economic evaluations have assessed the cost-effectiveness of prevention strategies in different populations. Although GBS has traditionally been considered a perinatal pathogen, the burden of invasive GBS disease among nonpregnant adults has been measured. Adverse outcomes of pregnancy attributable to GBS were addressed through a multicentre study which confirmed the important role of heavy colonisation with GBS in preterm low-birthweight deliveries. Finally, the pathogen itself has continued to evolve: new capsular serotypes described in the past decade are now causing an important proportion of clinical infections.